Navigation Links
Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
Date:2/20/2008

2,456 7,621 9,128

Other Product Lines 227 150 740 600

Non Core Revenue 9,241 10,307 36,723 40,478

Revenue $ 26,939 $ 25,431 $104,277 $ 99,241

OSTEOTECH, INC. and Subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEET

(dollars in thousands)

December 31,

2007 2006

Assets

Cash and cash equivalents $22,777 $17,946

Accounts receivable, net 19,353 18,507

Deferred processing costs 30,850 29,067

Inventories 1,171 1,005

Other current assets 3,957 2,795

Total current assets 78,108 69,320

Property, plant and equipment, net 34,508 36,340

Other assets 7,735 7,373

$120,351 $113,033

Liabilities and Stockholders' Equity

Accounts payable and accrued liabilities $19,364 $15,861

Current maturities of capital lease obligation 807 727

Total current liabilities 20,171 16,588

Capital lease obligation 14,070 14,876

Other liabilities 7,082 7,716

Total liabilities 41,323 39,180

Stockholders' equity 79,028 73,853

$120,351
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
2. Osteotech to Present at Sidoti Conference in San Francisco
3. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
4. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
6. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
7. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
10. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
11. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email: